Aromatase inhibitors in breast cancer: current and evolving roles.
The aromatase inhibitors are established first-line drugs for treating metastatic breast cancer in postmenopausal women, and are gaining acceptance as adjuvant treatment as well.
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.
John
J
Hill
Halle
H
Moore
D000616:Aminoglutethimide / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001141:Aromatase / Q000378:metabolism; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D017024:Chemotherapy, Adjuvant / Q000379:methods; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004967:Estrogens / Q000096:biosynthesis; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004967:Estrogens; D013629:Tamoxifen; D000616:Aminoglutethimide; D001141:Aromatase